Clinical Trial

Cannabidiol's Role in Dementia Management

Study acronym: MyC4D
Unknown Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated July 23, 2024 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This trial investigates the therapeutic benefits of cannabidiol (CBD) for Dementia patients in Malaysia. As dementia becomes increasingly prevalent worldwide, there's a pressing demand for impactful remedies. This research will delve into CBD's influence on cognitive functions, daily activities, mental health, and overall life quality of dementia sufferers. Utilizing a range of established assessment instruments, including the ADAS-COG subscale for cognitive effects, the NPI score for psychological well-being, and the QOLAD questionnaire for life quality, we aim to discern CBD's potential in ameliorating the conditions of those with dementia. This study's results could shape novel treatment methods and improved care for dementia patients, benefiting not just Malaysia but the world at large.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06514066
Lead Sponsor Hospital Pengajar Universiti Putra Malaysia
Collaborators: UPM Consultancy & Services Sdn. Bhd., Pure Life Collective Pte Ltd
Conditions Dementia, Vascular, Dementia, Mixed
Enrollment 486 participants
Start Date 2024-09-01
Primary Completion 2025-10-01 (estimated)
Study Completion 2025-10-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-23